Longer term follow-up of abdominal symptoms (CFAbd-Score) after initiation of Elexacaftor / Tezacaftor / Ivacaftor in adults with cystic fibrosis.

Caley, LR.; Gillgrass, L.; Zagoya, C.; Saumtally, H.; Duckstein, F.; H, W.; Mainz, JG.; Peckham, DG.

Longer term follow-up of abdominal symptoms (CFAbd-Score) after initiation of Elexacaftor / Tezacaftor / Ivacaftor in adults with cystic fibrosis.

All Authors

Caley, LR.

Gillgrass, L.

Zagoya, C.

Saumtally, H.

Duckstein, F.

H, W.

Mainz, JG.

Peckham, DG.

LTHT Author

Caley, Laura
Gillgrass, Lindsey
Saumtally, Hisham
Peckham, Daniel

LTHT Department

Cardio-Respiratory
Respiratory Medicine
Adult Cystic Fibrosis Unit

Non Medic

Dietitian
AHP Research Fellow
Research Nurse

Publication Date

2025

Item Type

Journal Article

Abstract

BACKGROUND: Whether improvements in gastrointestinal (GI) symptoms observed with Elexacaftor/Tezacaftor/Ivacaftor (ETI) treatment are sustained in the longer-term requires exploration. This study investigated how GI-symptoms change with longer-term ETI use in pancreatic insufficient adults with cystic fibrosis (awCF). METHODS: Participants completed up to three abdominal symptom questionnaires, employing the validated CFAbd-Score. Changes in total CFAbd-Score and its five domains, pain, gastroesophageal reflux-disease (GERD), disorders of bowel movement (DBM), disorders of appetite (DA) and quality of life (QOL), were analysed pre-ETI (T0) and at <=1.5 years (T1) and 2-4 years of ETI-therapy (T2). RESULTS: A total of 165 CFAbd-Scores from 68 participants were analysed (median age: 34 years; IQR: 28-39). Total CFAbd-Score significantly (p < 0.05) and clinically meaningfully decreased from 20.4 +/- 1.6 pre-ETI (median:40 weeks pre-treatment) to 15.3 +/- 1.9 and 16.8 +/- 1.6 at T1 (median: 25 weeks of ETI) and T2 (median: 148 weeks of ETI), respectively. The CFAbd-Score's domains DA and QoL only significantly decreased between T0 and T1, whereas DBM only significantly decreased after 2-4 years of ETI therapy (T2). GERD scores were significantly lower at both T1 and T2. CONCLUSION: While GI symptoms in awCF significantly improve within the first 1.5 years of ETI-therapy, they appear to somewhat wane with longer-term use, despite GI-symptom burden still being lower compared to pre-ETI. However, we cannot differentiate whether this results from reduced adherence, a decrease in ETI effects, or long-term changes in diet, gut microbiota or symptom perception. The longer-term impact of ETI and other potential modulator therapies on GI symptoms requires ongoing monitoring.